Japan Tissue Engineering Co., Ltd.
First Quarter Financial Results for Fiscal Year Ending March 2027 | Details of Revenue and Profit
J・TEC achieved an increase in revenue and operating profit in the first quarter of fiscal year ending March 2027. Revenue is unknown, and operating profit was 240 million yen, up YoY. Contributions from significant growth in Jack OA, successful in-house development, and effects of overseas strategic investments are noted.
Key Figures
- Revenue: Unknown
- Operating Profit: 240 million yen
- Adjustment Amount: Unknown
AI要約
Financial Overview
In the first quarter of fiscal year ending March 2027, J・TEC recorded increases in revenue and operating profit. While the specific revenue figure is unknown, operating profit reached 240 million yen, reflecting an increase from the same period last year. The main factors include significant growth in Jack OA revenue, successful in-house product development, and the effects of overseas strategic investments. Cost management and efficiency improvements have also contributed to enhanced profitability.
Future Outlook and Impact on Shareholders
The company plans to continue expanding overseas and its medical business, aiming for further increases in revenue and profit. Improvements in adjustment amounts and new business developments aim to strengthen the earnings foundation. For shareholders, sustained profit growth combined with expectations for dividend increases and stock price appreciation are anticipated. Management emphasizes balancing efficiency and investment to pursue sustainable growth.
J・TEC
Company overview · Stock price · Financial data · All IR
